Ampicillin + sulbactam

Generic Medicine Info
Hypersensitivity to ampicillin, sulbactam or other β-lactam antibacterials (e.g. penicillins, cephalosporins). History of cholestatic jaundice/hepatic dysfunction associated w/ ampicillin and sulbactam.
Special Precautions
Patient w/ infectious mononucleosis. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor haematologic, renal and hepatic function w/ prolonged therapy. Monitor for signs of anaphylaxis during 1st dose. Regular monitoring of hepatic function in patients w/ pre-existing hepatic impairment at regular intervals.
Adverse Reactions
Diarrhoea, nausea, vomiting, flatulence, abdominal discomfort/distension, rectal bleeding, glossitis, gastritis, stomatitis, black/hairy tongue, rash, urticaria, pruritus, dry skin, erythema multiforme, exfoliative dermatitis, cholestatic hepatitis and cholestasis; pain, phlebitis, thrombophlebitis and inflammation at inj site.
Potentially Fatal: Anaphylaxis, Clostridium difficile-associated diarrhoea, hepatotoxicity.
Drug Interactions
Increased and prolonged serum levels w/ probenecid. Increased incidence of rashes w/ allopurinol. May reduce effectiveness of oestrogen-containing OC. May increase risk of methotrexate toxicity. Bacteriostatic drugs (e.g. chloramphenicol) may interfere w/ the bactericidal effect of ampicillin. Additive effect w/ anticoagulants.
CIMS Class
ATC Classification
J01CG01 - sulbactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.
J01CA01 - ampicillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections.
S01AA19 - ampicillin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on ampicillin + sulbactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in